A cannabinoid is one of a great collection of complex chemical compounds that operates on cannabinoid receptors in cells that change neurotransmitter release in the brain. Cannabinoids for these receptors include the endocannabinoids, that are made naturally in the body by animals, the phytocannabinoids in cannabis and some other plants, and synthetic cannabinoids. The main cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive chemical in cannabis. Cannabidiol (CBD) is another main constituent of the plant and produces a non psychotic effect. This paper will review the neuroprotective allowances that cannabis feeds the brain to assure normal regulation against progressive multiple sclerosis (MS).
Here is the full scientific article if you wish to download it.
THC may have a neuroprotective effect against multiple sclerosis
MS is the main immune-controlled, demyelinating, neurodegenerative syndrome of the central nervous system. Chemicals within marijuana, most notably THC, can delay the mal-neurotransmissions that bring MS-related problems and medicinal marijuana is now legalised for the treatment of MS disorders. However, the biology suggests that the endocannabinoid system may give possible control to other aspects of syndrome. Although there is not a great deal of evidence that the cannabinoids from cannabis are having huge immunosuppressive activities that will spur on recurring autoimmunity, it is experimentally displayed that they might halt neurodegeneration that spurs on progressive disorders. Synthetic cannabidiol is displayed here to calm down the build up of a disability from the inflammatory chemical during recurring multiple sclerosis in mice. THC has been shown to delay clinical progression during MS in humans.
Cannabinoids as a potential anti MS drug
Despite the hope of marijuana to mediate progression in MS, it remains to be known whether similar experiments of THC in progressive MS, with a clear design, will be used again to produce legal treatments. This might be hard for investigator-led academic research because of the unsuccessful first trial, making it hard to accumulate the massive funds needed to undergo similar research. This failure in humans will most likely stop support for future basic science studies in this locus. After the initial failure of academic led-trials in muscle stiffness, concern was held due to the commercial evolution of similar products. However, advancement of patent-protected agents of cannabinoids and endocannabinoid changers may be one way to advance the commercial aspects of process of dissectioning the cannabinoid heart to fuel deliver a therapeutic for the onset of MS.